Neil Maresky, CEO Psyence Group | Spotlight Interview
Neil Maresky, CEO Psyence Group | Spotlight Interview [...]
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence Group Announces Private Placement
Psyence announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “Notes”).
Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain
Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.
Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit
Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.
Covid-19 steepens the trajectory of an already booming functional mushroom market
Covid-19 steepens the trajectory of an already booming functional [...]
In conversation with Neil van Rij on Psyence’s magic mushrooms
Neil van Rij is Psyence’s resident mycologist. In this interview he sheds some light on the mushrooms Psyence is growing at its state-of-the-art facility in Lesotho and what these mushrooms will be used for.
The potential for psychedelics as part of palliative care: Louis Schwartzberg talks to Dr. Dingle Spence
Our Western culture teaches us to push grief away, push death away and we do everything we can to distract ourselves from dealing with terrible pain, whether it is physical pain, grief pain or fear of death. I really see the future of psychedelics in helping us deal with existential distress.
Psyence Group Announces Commencement Of Trading On OTCQB And DTC Eligibility Of Common Shares In The United States Under The Ticker “PSYGF”
We are pleased to announce that, effective today, Psyence common shares have been approved for trading on the OTCQB® Venture Market (the “OTCQB”) under the symbol “PSYGF”.
Dr Dingle Spence to speak at two conferences on psychedelics
Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.